New York, NY, and Anaheim, CA, October 1, 2022 – Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced the formal launch of Innovation Fertility, a network of leading IVF clinics and laboratories, ahead of the American Society for Reproductive Medicine (“ASRM”) Scientific Congress & Expo. in Anaheim, CA, October 22-26, 2022. This is the premier event for reproductive medicine, drawing top experts from around the world.

Innovation Fertility is led by a dynamic and seasoned team of reproductive health and business professionals with years of experience in building successful fertility practices. Their decades of expertise spans laboratory design, technology implementation, strategic planning, and operations support.

“We have been working toward this pivotal moment for some time,” says Dwight P. Ryan, CEO of Innovation Fertility. “Our mission is to leverage our collective experience to empower our partner practices and help deliver better outcomes for more families. But we want these practices to retain what makes them unique and trusted by their patient population.”    

The forward-thinking theme of the ASRM 2022 meeting — “Genes, Gametes, and Genetics: What Will the Future Hold?” —  is in-step with the organization’s new core messaging, which asks practices to imagine “What IF?” Innovation Fertility is on the other side of that question, offering greater efficacy, more support, and better technology. In a time when much value is often placed on the disruptive era of fertility care, Innovation places greater emphasis on following the science and embracing innovative, evidence-based solutions.

“For years, the leadership team has brought the best technology and laboratory practices to fertility clinics,” says Dr. Kathleen Miller, Chief Science Officer at Innovation Fertility. “We are known for being data-driven, science-first insiders. It’s exciting to have a brand that elevates our work and commitment to our practice partners, but we’re also proud to be more than a brand. Years of research, dedication, and big thinking have gotten us here.”

Though ASRM will mark the organization’s formal debut, Innovation Fertility has already been working with fertility practices across the country, giving them the autonomy to run day-to-day operations as they see fit, while bolstering them with the additional support they need to streamline internal operations and scale accordingly.

Learn more about Innovation Fertility at ASRM, October 22-26, 2022  at booth 1502.


Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit:


Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine some of the premier reproductive endocrinologists of the world with the most experienced laboratory managers and operators in the space, resulting in exceptional medical care and an unparalleled patient experience. For more information, visit:


This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Innovation Fertility following its acquisition by Albaron Partners. If any of these risks or uncertainties materialize, or if any of Innovation Fertility’s or Albaron Partners’ assumptions prove incorrect, Innovation Fertility’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Innovation Fertility and Albaron Partners as of the date of this communication, and Innovation Fertility and Albaron Partners do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.